Photo Courtesy of Johnson & Johnson

Johnson & Johnson Starts Ebola Vaccine Clinical Tests

Jan. 6, 2015
The company has already produced more than 400,000 doses, and two million courses will be ready by the end of the year. If necessary the company said it can make five million doses within 12 to 18 months.

Johnson & Johnson (IW 500/17) said Tuesday that it has started human trials on a possible vaccine against Ebola.

The Phase I testing is being carried out by the Oxford Vaccine Group at Britain's Oxford University. 

The tests, involving 72 healthy volunteers, will examine how their bodies tolerate the potential vaccine.

Johnson & Johnson said at the end of October it would spend up to $200 million to speed up and expand its Ebola vaccine program.

The company hopes to move on to studies on large groups of patients by April.

It said it has already produced more than 400,000 doses, and two million courses will be ready by the end of the year. 

If necessary, Johnson & Johnson said it can make five million doses within 12 to 18 months.

The worst Ebola outbreak on record has killed 8,153 people over the past year. Liberia has seen the highest fatality rate with 3,471 deaths, followed by Sierra Leone and Guinea.

Copyright Agence France-Presse, 2015

Popular Sponsored Recommendations

How Digital Twin Technology is Empowering Manufacturers

Sept. 27, 2023
This FAQ delves into why this technology offers business value and considerations toward implementation.

Why DataOps may be the key to unlocking the full potential of digital transformation

Nov. 3, 2023
Read the 2023 market survey conducted by IndustryWeek

Decarbonization Navigator: A Toolkit for Organizations

Sept. 28, 2023
The increasing urgency of addressing climate change along with stakeholder pressures are driving the need for organizations to prioritize decarbonization. Discover how to start...

Food and Beverage 2024 Trends and Outlook for North America

Oct. 29, 2023
Ready to hear what 200 of your peers said are the top challenges and opportunities in 2024? Don’t fall behind. Uncover actionable insights to better prepare for 2024 in this whitepaper...

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!